Thermo Fisher Scientific’s acquisition of The Binding Site brings a company that specializes in diagnostic tests for blood cancers and immune system disorders. It’s Thermo Fisher’s biggest acquisition since its 2021 buyout of contract research organization PPD.
The current pandemic, which has caused treatment delays, is simply another reason that home-based treatment options should become more readily available to cancer patients.
Munck Wilson Mandala Partner Greg Howison shared his perspective on some of the legal ramifications around AI, IP, connected devices and the data they generate, in response to emailed questions.
Here's a look at a company that could seriously be in the running for Theranos' biggest competitor.
NOWDiagnostics CEO Kevin Clark shares about the company's single fingertip-prick blood testing that could change the way we diagnose diseases as well as detect pregnancy.